These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 15694747)

  • 1. Comprehensive risk reduction of cardiovascular risk factors in the diabetic patient: an integrated approach.
    Srikanth S; Deedwania P
    Cardiol Clin; 2005 May; 23(2):193-210. PubMed ID: 15694747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of glycemic treatment choices on cardiovascular complications in type 2 diabetes.
    Weiss IA; Valiquette G; Schwarcz MD
    Cardiol Rev; 2009; 17(4):165-75. PubMed ID: 19525678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia.
    Milicevic Z; Raz I; Beattie SD; Campaigne BN; Sarwat S; Gromniak E; Kowalska I; Galic E; Tan M; Hanefeld M
    Diabetes Care; 2008 Feb; 31 Suppl 2():S155-60. PubMed ID: 18227478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary prevention of cardiovascular disease in type 2 diabetes and prediabetes: a cardiologist's perspective.
    Cubbon R; Kahn M; Kearney MT
    Int J Clin Pract; 2008 Feb; 62(2):287-99. PubMed ID: 18036163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
    Robins SJ; Collins D; Nelson JJ; Bloomfield HE; Asztalos BF
    Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1172-8. PubMed ID: 18356553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventing diabetic complications: a primary care perspective.
    Zimmet P
    Diabetes Res Clin Pract; 2009 May; 84(2):107-16. PubMed ID: 19278746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the most effective strategy for managing diabetic dyslipidaemia?
    Reasner CA
    Atheroscler Suppl; 2005 Sep; 6(3):21-7. PubMed ID: 16054442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study.
    Du X; Ninomiya T; de Galan B; Abadir E; Chalmers J; Pillai A; Woodward M; Cooper M; Harrap S; Hamet P; Poulter N; Lip GY; Patel A;
    Eur Heart J; 2009 May; 30(9):1128-35. PubMed ID: 19282274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
    Steinmetz A
    Diabetes Metab Res Rev; 2008; 24(4):286-93. PubMed ID: 18273835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FIELDS of dreams, fields of tears: a perspective on the fibrate trials.
    Wierzbicki AS
    Int J Clin Pract; 2006 Apr; 60(4):442-9. PubMed ID: 16620358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiometabolic determinants of mortality in a geriatric population: is there a "reverse metabolic syndrome"?
    Vischer UM; Safar ME; Safar H; Iaria P; Le Dudal K; Henry O; Herrmann FR; Ducimetière P; Blacher J
    Diabetes Metab; 2009 Apr; 35(2):108-14. PubMed ID: 19237305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.
    Grover SA; Kaouache M; Joseph L; Barter P; Davignon J
    Arch Intern Med; 2009 Oct; 169(19):1775-80. PubMed ID: 19858435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Microalbuminuria in diabetes: setting the points for treatment].
    Lehnert H; Klose S; Lobmann R; Zehnder D
    MMW Fortschr Med; 2006 May; 148(21):28-30, 33; quiz 34. PubMed ID: 16796185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dyslipidaemia in diabetic patients: time for a rethink.
    Shepherd J
    Diabetes Obes Metab; 2007 Sep; 9(5):609-16. PubMed ID: 17697054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Type 2 diabetes mellitus and cardiovascular diseases: evaluation, treatment and prevention strategies].
    Mosseri MM; Fisman EZ; Tenenbaum A
    Harefuah; 2006 Feb; 145(2):141-6, 164. PubMed ID: 16509421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation critique of state of the art dyslipidemia management in general and with a special emphasis on the Indian population.
    Whayne TF
    Indian Heart J; 2007; 59(3):218-25. PubMed ID: 19124929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
    Goff DC; Gerstein HC; Ginsberg HN; Cushman WC; Margolis KL; Byington RP; Buse JB; Genuth S; Probstfield JL; Simons-Morton DG;
    Am J Cardiol; 2007 Jun; 99(12A):4i-20i. PubMed ID: 17599424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin resistance, diabetes and cardiovascular risk: approaches to treatment.
    Rosenberg DE; Jabbour SA; Goldstein BJ
    Diabetes Obes Metab; 2005 Nov; 7(6):642-53. PubMed ID: 16219008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.